Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

a technology which is applied in the field of gene and protein expression profiles associated with the therapeutic efficacy of irinotecan, can solve the problems that irinotecan often experience recurrence of disease or disease-related death

Inactive Publication Date: 2008-03-27
NUCLEA BIOMARKERS
View PDF31 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients having tumors that are non-responsive to irinotecan often experience recurrence of their disease or disease-related death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
  • Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan

Examples

Experimental program
Comparison scheme
Effect test

examples

[0080] A series of prognostic factors were tested in order to validate the efficacy of the gene / protein expression profile (GPEP) of the present invention for predicting the therapeutic response of irinotecan therapy. The expression levels of these factors, consisting of the twenty-two (22) proteins in the present GPEP listed in Table 2 (which includes seventeen differentially expressed proteins and five reference proteins), was determined by an immunohistochemical methodology in biopsy tissue samples obtained from late-stage colon cancer patients whose treatment with irinotecan had been successful, as well as samples from patients whose treatment was unsuccessful, e.g., who had experienced late recurrence (LRec) or disease-related death (DRD) associated with the therapy. For purposes of selecting the patients for the study, irinotecan therapy was determined to have failed if a recurrence was present within three years of diagnosis.

[0081] According to the current prescribing inform...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and / or protein expression profiles and assays for identifying the presence of a gene and / or protein expression profile in a patient sample.

Description

RELATED APPLICATIONS [0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. provisional Application Ser. No. 60 / 846,298 filed Sep. 21, 2006 and Application Ser. No. 60 / 906,438 filed Mar. 12, 2007, the entirety of which are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] Patients diagnosed with cancer are faced with costly and often painful treatment options. These treatments may be ineffective in a subpopulation of patients, and as a result, these patients endure these treatments without little or no therapeutic benefit. Some patients may react adversely to certain agents causing additional suffering and possibly death. [0003] Ineffective treatment also is problematic because time is a key variable when treating cancer. A treatment provider has a far greater chance of containing and managing the disease if the cancer is diagnosed at an early stage and treated with a therapeutically effective agent. An agent may provide great therapeutic benefits...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68C40B40/08
CPCC12Q1/6886C12Q2600/106G01N2800/52G01N33/6803C12Q2600/158
Inventor MURACA, PATRICK J.
Owner NUCLEA BIOMARKERS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com